RAPP
Rapport Therapeutics, Inc. Common StockNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.61B
P/E Ratio
—
EPS
$-2.88
Beta
—
52W High
$42.27
52W Low
$7.73
50-Day MA
$28.55
200-Day MA
$24.09
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Rapport Therapeutics, Inc. Common Stock
Rapport Therapeutics, Inc. is a cutting-edge biotechnology firm specializing in the development of innovative therapeutics aimed at addressing neurodegenerative disorders, with a particular focus on Alzheimer's disease and related cognitive impairments. The company leverages its proprietary drug candidates and advanced technology platforms to drive robust scientific research and clinical validation, positioning itself as a leader in neuroscience innovation. By targeting significant unmet medical needs, Rapport is poised to make meaningful contributions to the evolving biotech landscape, offering potential solutions for patients suffering from debilitating cognitive conditions.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-124.08M |
| Operating Margin | 0.00% |
| Return on Equity | -28.20% |
| Return on Assets | -18.90% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $10.14 |
| Price-to-Book | 3.31 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $47.79M |
| Float | $30.76M |
| % Insiders | 4.65% |
| % Institutions | 107.64% |
Analyst Ratings
Consensus ($52.22 target)
1
Strong Buy9
BuyData last updated: 4/9/2026